Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
NCT06570798Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Jul 2025
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of inebilizumab, blinatumomab in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), sponsored by Amgen. Started Jul 2025; status: recruiting.
02
Drugs
inebilizumabblinatumomab
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06570798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570798.